This trial will study the safety and effectiveness of a new medicine to treat DLBCL before receiving CAR-T cell therapy.
- Non-Hodgkin's Lymphoma
0 Primary · 5 Secondary · Reporting Duration: up to 27months
1 Treatment Group
1 of 1
27 Total Participants · 1 Treatment Group
Primary Treatment: Pre-Modulation Treatment · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has Pre-Modulation Treatment obtained regulatory approval from the FDA?
"Pre-Modulation Treatment received a score of 2 on Power's safety scale, as Phase 2 trials provide some evidence for its safety but no concrete proof yet that it is efficacious." - Anonymous Online Contributor
Are there any available vacancies to join this research project?
"Indeed, clinicaltrials.gov confirms that this medical experiment is still seeking participants. The trial was initially uploaded on February 23rd 2023 and most recently revised on the following day. 27 volunteers are needed from a single enrolment location." - Anonymous Online Contributor
How many individuals have participated in this clinical experiment?
"Affirmative, data hosted on clinicaltrials.gov shows that this medical trial is still identifying potential participants. It was first published on February 23rd 2023 and last updated a day later. The research team are currently looking for 27 individuals from 1 site." - Anonymous Online Contributor